

# Stanford

---



## Dean W. Felsher

Professor of Medicine (Oncology) and of Pathology  
Medicine - Oncology

### CONTACT INFORMATION

- **Alternate Contact**

Leslie Quiroz

**Email** lquiroz@stanford.edu

**Tel** 650-725-6454

### Bio

---

#### ACADEMIC APPOINTMENTS

- Professor, Medicine - Oncology
- Professor, Pathology
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Faculty Fellow, Sarafan ChEM-H
- Member, Stanford Cancer Institute

#### ADMINISTRATIVE APPOINTMENTS

- Director of Translational Research and Applied Medicine, Department of Medicine, Stanford University School of Medicine, (2011- present)
- Co-Director Cancer Nanotechnology Program, Department of Radiology, Stanford School of Medicine, (2016- present)
- Director of Admissions/Associate Director, Medical Scientist Training Program, (2017- present)
- Director of Advanced Residency Training Program, Stanford University School of Medicine, (2018- present)
- Co-Director of Spectrum KL2 Mentored Development Program, Stanford University, School of Medicine, (2019- present)

#### HONORS AND AWARDS

- Elected Member, Association of American Physicians (2011)
- Translational Research Award, Burroughs Wellcome Trust (2005-2011)
- Elected Member, American Society of Clinical Investigation (2005)
- Clinical Investigator Award, Damon Runyon Foundation (2003-2008)
- Charles Carrington Prize, Stanford University (2002)
- Esther Ehrman Faculty Scholar Award, Stanford University (2000-2003)
- Physician Post-Doctoral Award, Howard Hughes Medical Institute (1997-1999)
- Emil Bogen Award, University of California, Los Angeles (1992)

- Honors, University of Chicago (1985)

## PROFESSIONAL EDUCATION

- BA, University of Chicago (1985)
- MD PhD, UCLA , Medicine/Molecular Biology (1992)

## LINKS

- Felsher Laboratory: [http://med.stanford.edu/labs/dean\\_felsher/](http://med.stanford.edu/labs/dean_felsher/)

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

My laboratory studies how oncogenes such as MYC initiate and maintain cancer. In particular we have shown that shutting down oncogenes even for a brief time can reverse cancer or elicit "Oncogene Addiction"

For a recent review of our work please see: The MYC oncogene - the grand orchestrator of cancer growth and immune evasion Nature Reviews Clinical Oncology, 2022

Examples of project in my laboratory:

We are studying basic mechanisms of Oncogene Addiction: the role of Self-renewal/Stemness, Metabolism, Host Immune System, Protein Biogenesis, Microbiome, Extracellular Vesicles.

We are developing novel therapeutics using small molecules, nanoparticles, proteins/peptides that can be used to target oncogenes and/or restore the immune response against cancer.

We are developing new diagnostic and imaging methods such as PET, Mass Spec, Nanoproteomics.

### CLINICAL TRIALS

- Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy, Not Recruiting
- Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma, Not Recruiting
- Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma, Not Recruiting

## Teaching

---

### COURSES

#### 2025-26

- Biologics, advanced therapeutics and drug delivery methods: TRAM 211 (Aut)
- Biotechnology Law: TRAM 283 (Spr)
- Drug Development and Clinical Trials: TRAM 223B (Win)
- Fundamentals of Drug Discovery: TRAM 223A (Aut)
- Pharmaceutical and Healthcare Econ of Drug Commercialization: TRAM 223C (Spr)
- Translational Proteomics and Genomics: TRAM 212B (Win)

- Translational Research and Applied Medicine: TRAM 121, TRAM 221 (Aut, Win, Spr)

#### **2024-25**

- Biologics, advanced therapeutics and drug delivery methods: MED 211 (Aut, Spr)
- Biotechnology Law: MED 283 (Spr)
- Commercialization and Future Healthcare Trends: MED 223C (Spr)
- Drug Development and Clinical: MED 223B (Win)
- Drug Discovery: MED 223A (Aut, Spr)
- Translational Assay Technologies: MED 212A (Spr)
- Translational Research and Applied Medicine: MED 121, MED 221 (Aut, Win, Spr, Sum)

#### **2023-24**

- Biotechnology Law: MED 283 (Spr)
- Current Topics in Applied Medicine: MED 211 (Aut)
- MTRAM A: Translational Research Methods and Technologies: Cell Based Methods: MED 212A (Aut)
- Stanford CTSA Scholars Seminar: EPI 229 (Aut, Win, Spr)
- The A to Z of Translational Medicine: Emerging Trends in Drug Development and Next-gen Innovations: MED 251C (Spr)
- The A to Z of Translational Medicine: Fundamentals and Technical Considerations of Drug Development: MED 251A (Aut)
- The A to Z of Translational Medicine: Strategic Challenges in Drug Development: MED 251B (Win)
- Translational Research and Applied Medicine: MED 121, MED 221 (Win, Spr)

#### **2022-23**

- Current Topics in Applied Medicine: MED 211 (Aut)
- MTRAM A: Translational Research Methods and Technologies: Cell Based Methods: MED 212A (Aut)
- Stanford CTSA Scholars Seminar: EPI 229 (Aut, Win, Spr)
- TR Technologies B - (Translational Proteomics): MED 212B (Win)
- Translational Research and Applied Medicine: MED 121, MED 221 (Aut, Win, Spr)

## **STANFORD ADVISEES**

### **Med Scholar Project Advisor**

Nadia Kirmani, Patton Nguyen

### **Postdoctoral Faculty Sponsor**

Alessia Felici, Harsh Goar, Vishnu Priya Kanakaveti, Yan Zhao, Selene Zhou

### **Postdoctoral Research Mentor**

Alessia Felici, Vishnu Priya Kanakaveti, Selene Zhou

## **GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS**

- Cancer Biology (Phd Program)
- Immunology (Phd Program)
- Medicine (Masters Program)
- Oncology (Fellowship Program)

## Publications

### PUBLICATIONS

- **EcDNA-borne structural variants drive oncogenic fusion transcript amplification.** *Cell*  
Yi, H., Zhang, S., Swinderman, J., Wang, Y., Kanakaveti, V., Hung, K. L., Tsz-Lo Wong, I., Srinivasan, S., Curtis, E. J., Bhargava-Shah, A., Li, R., Jones, M. G., Luebeck, et al  
2026
- **Sex disparity in survival outcomes of advanced gastric adenocarcinoma.** *BJC reports*  
Pan, M., Tong, M. M., Stover, J., Huang, T., Dang, A., Jiang, C., Achacoso, N. S., Bien, J., Solorzano, A. V., Tse, P., Chung, E., Kanakaveti, V. P., Felsher, et al  
2025; 3 (1): 58
- **Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers.** *Cell chemical biology*  
Mahauad-Fernandez, W. D., Yang, Y. C., Lai, I., Park, J., Yao, L., Evans, J. W., Atibalentja, D. F., Chen, X., Kanakaveti, V., Zhao, Z., Burnett, G. L., Lee, B. J., Dinglasan, et al  
2025
- **Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas.** *BJC reports*  
Pan, M., Dang, A., Huang, T., Stover, J., Tong, M. M., Jiang, C., Achacoso, N. S., Bien, J., Solorzano, A. V., Tse, P., Chung, E., Kanakaveti, V. P., Felsher, et al  
2025; 3 (1): 31
- **Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma.** *Nature communications*  
Zhang, J., Yang, J., Luo, J., Wu, W., Luo, H., Wei, W., Lyu, H., Wang, Y., Yi, H., Zhang, Y., Fan, Z., Lyu, H., Kanakaveti, et al  
2025; 16 (1): 3315
- **Prognostic and biological divergence of upper gastrointestinal adenocarcinomas.**  
Dang, A., Pan, M., Stover, J., Huang, T., Tong, M., Jiang, C., Habel, L. A., Achacoso, N., Bien, J., Solorzano-Pinto, A., Tse, P., Chung, E., Felsher, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 350
- **MYC Inactivation Restores Immune Surveillance in a Transgenic Mouse Model of T-Cell Acute Lymphoblastic Lymphoma**  
Atibalentja, D. F., Kanakaveti, V., Yao, L. E., Felsher, D. W.  
ELSEVIER.2024
- **Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.** *Nature cancer*  
Lemaitre, L., Adeniji, N., Suresh, A., Reguram, R., Zhang, J., Park, J., Reddy, A., Trevino, A. E., Mayer, A. T., Deutzmann, A., Hansen, A. S., Tong, L., Arjunan, et al  
2024
- **Hostile Takeover: Diagnosing Cancer from within Using a Cancer-Activated Genetic Construct as a Novel Imaging Platform for NSCLC Detection**  
Goryawala, M., Lee, H., Tong, L., Patil, T., Harwig, A., Xia, C., Ramachandran, S., Wu, X., Wodziak, D., Ananthanarayanan, B., Morisot, N., Felsher, D. W., Sproul, et al  
CELL PRESS.2024: 227
- **A big step for MYC-targeted therapies.** *Trends in cancer*  
Atibalentja, D. F., Deutzmann, A., Felsher, D. W.  
2024
- **Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.** *Nature communications*  
Deutzmann, A., Sullivan, D. K., Dhanasekaran, R., Li, W., Chen, X., Tong, L., Mahauad-Fernandez, W. D., Bell, J., Mosley, A., Koehler, A. N., Li, Y., Felsher, D. W.  
2024; 15 (1): 963

- **Single-Nucleus Chromatin Accessibility Identifies a Critical Role for TWIST1 in IPF Myofibroblast Activity.** *The European respiratory journal*  
Valenzi, E., Bahudhanapati, H., Tan, J., Tabib, T., Sullivan, D. I., Nouraie, M., Sembrat, J., Fan, L., Chen, K., Liu, S., Rojas, M., Lafargue, A., Felsher, et al  
2023
- **MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.** *Proceedings of the National Academy of Sciences of the United States of America*  
Smith, B. A., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluinage, J. V., Swaminathan, S., Riley, N. M., Rajan, et al  
2023; 120 (11): e2215376120
- **MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma that is Reversible Through Restoration of Pro-Inflammatory Macrophages.** *Cancer research*  
Dhanasekaran, R., Hansen, A. S., Park, J., Lemaitre, L., Lai, I., Adeniji, N., Kuruvilla, S., Suresh, A., Zhang, J., Swamy, V., Felsher, D. W.  
2022
- **MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.** *Oncogene*  
Sullivan, D. K., Deutzmann, A., Yarbrough, J., Krishnan, M. S., Gouw, A. M., Bellovin, D. I., Adam, S. J., Liefwalker, D. F., Dhanasekaran, R., Felsher, D. W.  
2022
- **Na<sup>+</sup>/H<sup>+</sup>-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells.** *Cancer research communications*  
Gong, Y., Shao, H., Li, Y., Brafford, P., Stine, Z. E., Sun, J., Felsher, D. W., Orange, J. S., Albelda, S. M., Dang, C. V.  
2022; 2 (8): 842-856
- **Bi-steric mTORC1 inhibitor RMC-6272 synergizes with immune checkpoint inhibitors to induce sustained regression of MYC-driven hepatocellular carcinoma**  
Mahauad-Fernandez, W. D., Yang, Y. C., Lai, I., Park, J., Yao, L., Evans, J. W., Smith, J. A., Singh, M., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2022
- **A more sensitive approach to cancer imaging using cancer-activated PET reporters**  
Harwig, A., Wang, M., Tong, L., Nieu, R., Vy Nguyen, Felsher, D., Suhy, D.  
AMER ASSOC CANCER RESEARCH.2022
- **Azopodophyllotoxin Causes Lymphoma and Kidney Cancer Regression by Disrupting Tubulin and Monoglycerols.** *ACS medicinal chemistry letters*  
Gouw, A. M., Kumar, V., Resendez, A., Alvina, F. B., Liu, N. S., Margulis, K., Tong, L., Zare, R. N., Malhotra, S. V., Felsher, D. W.  
2022; 13 (4): 615-622
- **Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.** *Nanotheranostics*  
Lee, C. K., Atibalentja, D. F., Yao, L. E., Park, J., Kuruvilla, S., Felsher, D. W.  
2022; 6 (3): 243-255
- **Tackling heterogeneity in treatment-resistant breast cancer using a broad-spectrum therapeutic approach.** *Cancer drug resistance (Alhambra, Calif.)*  
Lowe, L., LaValley, J. W., Felsher, D. W.  
2022; 5 (4): 917-925
- **Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.** *Frontiers in oncology*  
Tong, L., Shan, M., Zou, W., Liu, X., Felsher, D. W., Wang, J.  
2022; 12: 904969
- **DISTINCT IMMUNE MECHANISMS OF COMBINED PD-L1 AND CTLA-4 BLOCKADE IN HEPATOCELLULAR CARCINOMA (HCC)**  
Dhanasekaran, R., Hansen, A., Park, J., Lai, I., Adeniji, N., Kuruvilla, S., Felsher, D.  
WILEY.2021: 110A
- **The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.** *Nature reviews. Clinical oncology*  
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., Felsher, D. W.  
2021

- **A bi-steric mTORC1 inhibitor that selectively reactivates 4EBP1 and induces regression of MYC-driven hepatocellular carcinoma.** Mahauad-Fernandez, W. D., Yang, Y. C., Lai, I., Park, J., Evans, J. W., Singh, M., Smith, J. A., Felsher, D. W. AMER ASSOC CANCER RESEARCH.2021
- **Twist1 is required for the development of UVB-induced squamous cell carcinoma.** *Molecular carcinogenesis* Eguiarte-Solomon, F., Blazanin, N., Rho, O., Carbajal, S., Felsher, D. W., Tran, P. T., DiGiovanni, J. 2021
- **Smart Self-Assembly Amphiphilic Cyclopeptide-Dye for Near-Infrared Window-II Imaging.** *Advanced materials (Deerfield Beach, Fla.)* Chen, H., Shou, K., Chen, S., Qu, C., Wang, Z., Jiang, L., Zhu, M., Ding, B., Qian, K., Ji, A., Lou, H., Tong, L., Hsu, et al 2021: e2006902
- **A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation.** *Scientific reports* Hori, S. S., Tong, L. n., Swaminathan, S. n., Liebersbach, M. n., Wang, J. n., Gambhir, S. S., Felsher, D. W. 2021; 11 (1): 1341
- **Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.** *Methods in molecular biology (Clifton, N.J.)* Mahauad-Fernandez, W. D., Rakhra, K., Felsher, D. W. 2021; 2318: 297-312
- **Mitochondrial copper depletion suppresses triple-negative breast cancer in mice.** *Nature biotechnology* Cui, L., Gouw, A. M., LaGory, E. L., Guo, S., Attarwala, N., Tang, Y., Qi, J., Chen, Y., Gao, Z., Casey, K. M., Bazhin, A. A., Chen, M., Hu, et al 2020
- **MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC MOLECULAR THERAPY-NUCLEIC ACIDS** Dhanasekaran, R., Park, J., Yevtodiynko, A., Bellovin, D. I., Adam, S. J., Rajan, A., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., Gryanzov, S., Felsher, D. W. 2020; 21: 850–59
- **MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC.** *Molecular therapy. Nucleic acids* Dhanasekaran, R., Park, J., Yevtodiynko, A., Bellovin, D. I., Adam, S. J., Kd, A. R., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., Gryanzov, S., Felsher, D. W. 2020; 21: 850–59
- **MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.** *Nature communications* Swaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Fernandez, W. D., Liefwalker, D. F., Horton, C., Mosley, A., Liebersbach, M., Maecker, H. T., Felsher, D. W. 2020; 11 (1): 2860
- **O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.** Shiraishi, T., Tran, P. T., Malek, R., Lafargue, A., Barbhuiya, M., Wang, X., Simons, B., Ballew, M., Nugent, K., Groves, J., Williams, R., Wang, H., Verdone, et al AMER ASSOC CANCER RESEARCH.2020: 59
- **The gastrointestinal microbiota controls cancer cell intrinsic mechanisms to promote the progression of acute lymphoblastic leukemia.** Mahauad-Fernandez, W., Zlithi, S., Bhatt, A., Felsher, D. AMER ASSOC CANCER RESEARCH.2020: 58–59
- **The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology* Smith, M. T., Guyton, K. Z., Kleinstreuer, N., Borrel, A., Cardenas, A., Chiu, W. A., Felsher, D. W., Gibbons, C. F., Goodson, W. H., Houck, K. A., Kane, A., La Merrill, M. A., Lebrec, et al 2020
- **MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity.** *eLife* Dhanasekaran, R., Baylot, V., Kim, M., Kuruvilla, S., Bellovin, D. I., Adeniji, N., Rajan Kd, A., Lai, I., Gabay, M., Tong, L., Krishnan, M., Park, J., Hu, et al

2020; 9

- **Genomic analysis of Vascular Invasion in Hepatocellular Carcinoma (HCC) Reveals Molecular Drivers and Predictive Biomarkers.** *Hepatology (Baltimore, Md.)*  
Krishnan, M. S., Rajan Kd, A. n., Park, J. n., Arjunan, V. n., Garcia Marques, F. J., Bermudez, A. n., Girvan, O. A., Hoang, N. S., Yin, J. n., Nguyen, M. H., Kothary, N. n., Pitteri, S. n., Felsher, et al  
2020
- **The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?** *Cancer research*  
Mahauad-Fernandez, W. D., Felsher, D. W.  
2020
- **CROSS-SPECIES COMPREHENSIVE PROTEOMIC ANALYSIS OF HEPATOCELLULAR CARCINOMA (HCC) TO IDENTIFY PLASMA BIOMARKERS OF VASCULAR INVASION**  
Krishnan, M., Arjunan, V., Kothary, N., Felsher, D., Dhanasekaran, R.  
WILEY.2019: 74A
- **A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma** *HEPATOLOGY*  
Dhanasekaran, R., Felsher, D. W.  
2019; 70 (3): 1056–58
- **Oncogene MYC regulates lipogenesis essential for neoplastic growth**  
Margulis, K., Gouw, A., Liu, N., Felsher, D., Zare, R.  
AMER CHEMICAL SOC.2019
- **The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth.** *Cell metabolism*  
Gouw, A. M., Margulis, K., Liu, N. S., Raman, S. J., Mancuso, A., Toal, G. G., Tong, L., Mosley, A., Hsieh, A. L., Sullivan, D. K., Stine, Z. E., Altman, B. J., Schulze, et al  
2019
- **MYC regulates the HIF-2alpha stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells.** *Cancer research*  
Das, B., Pal, B., Bhuyan, R., Li, H., Sarma, A., Gayan, S., Talukdar, J., Sandhya, S., Bhuyan, S., Gogoi, G., Gouw, A. M., Baishya, D., Gotlib, et al  
2019
- **Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression** *SCIENTIFIC REPORTS*  
Yang, P., Jiang, Y., Pan, Y., Ding, X., Rhea, P., Ding, J., Hawke, D. H., Felsher, D., Narla, G., Lu, Z., Lee, R. T.  
2019; 9
- **A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC).** *Hepatology (Baltimore, Md.)*  
Dhanasekaran, R., Felsher, D. W.  
2019
- **Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.** *Cell chemical biology*  
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H., Neel, D. V., Freeman, D. B., Pop, et al  
2019
- **Conditional Upregulation of IFN-α Alone Is Sufficient to Induce Systemic Lupus Erythematosus.** *Journal of immunology (Baltimore, Md. : 1950)*  
Akiyama, C. n., Tsumiyama, K. n., Uchimura, C. n., Honda, E. n., Miyazaki, Y. n., Sakurai, K. n., Miura, Y. n., Hashiramoto, A. n., Felsher, D. W., Shiozawa, S. n.  
2019
- **Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index.** *Scientific reports*  
Li, Y. n., Thomas, D. n., Deutzmann, A. n., Majeti, R. n., Felsher, D. W., Dill, D. L.  
2019; 9 (1): 16775
- **Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression.** *Scientific reports*  
Yang, P. n., Jiang, Y. n., Pan, Y. n., Ding, X. n., Rhea, P. n., Ding, J. n., Hawke, D. H., Felsher, D. n., Narla, G. n., Lu, Z. n., Lee, R. T.

2019; 9 (1): 6428

- **MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies**  
Swaminathan, S., Heftdal, L., Liefwalker, D. F., Dhanasekaran, R., Deutzmann, A., Horton, C., Mosley, A., Liebersbach, M., Maecker, H. T., Felsher, D.  
AMER SOC HEMATOLOGY.2018
- **Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma.** *Journal for immunotherapy of cancer*  
Lai, I., Swaminathan, S., Baylot, V., Mosley, A., Dhanasekaran, R., Gabay, M., Felsher, D. W.  
2018; 6 (1): 125
- **O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis** *JOURNAL OF CLINICAL INVESTIGATION*  
Taparra, K., Wang, H., Malek, R., Lafargue, A., Barbhuiya, M. A., Wang, X., Simons, B. W., Ballew, M., Nugent, K., Groves, J., Williams, R. D., Shiraishi, T., Verdone, et al  
2018; 128 (11): 4924–37
- **The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma** *ONCOGENE*  
Miess, H., Dankworth, B., Gouw, A. M., Rosenfeldt, M., Schmitz, W., Jiang, M., Saunders, B., Howell, M., Downward, J., Felsher, D. W., Peck, B., Schulze, A.  
2018; 37 (40): 5435–50
- **MYC-driven lymphomas suppress NK surveillance by blocking maturation of early NK cells**  
Heftdal, L. D., Swaminathan, S., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2018
- **The MYC oncogene is a global regulator of the immune response** *BLOOD*  
Casey, S. C., Baylot, V., Felsher, D. W.  
2018; 131 (18): 2007–15
- **Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression** *CANCER IMMUNOLOGY IMMUNOTHERAPY*  
Hebb, J. P. O., Mosley, A. R., Vences-Catalan, F., Rajasekaran, N., Rosen, A., Ellmark, P., Felsher, D. W.  
2018; 67 (1): 47–60
- **Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).** *Oncotarget*  
Dhanasekaran, R. n., Gabay-Ryan, M. n., Baylot, V. n., Lai, I. n., Mosley, A. n., Huang, X. n., Zabudoff, S. n., Li, J. n., Kaimal, V. n., Karmali, P. n., Felsher, D. W.  
2018; 9 (5): 5517–28
- **MYC through HIF-2 alpha regulates the altruistic stemness program in human leukemia stem cells.**  
Pal, B., Sarma, A., Talukdar, J., Bhuyan, S., Sandhya, S., Gayan, S., Gogoi, G., Baishya, D., Katak, A., Felsher, D. W., Das, B.  
AMER ASSOC CANCER RESEARCH.2017: 61–62
- **MYC is the master switch between tumor dormancy and relapse in Hepatocellular carcinoma (HCC)**  
Dhanasekaran, R., Baylot, V., Mosley, A., Felsher, D.  
WILEY.2017: 966A
- **DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma** *ONCOTARGET*  
Poole, C. J., Zheng, W., Lodh, A., Yevtodiynenko, A., Liefwalker, D., Li, H., Felsher, D. W., van Riggelen, J.  
2017; 8 (44): 76898–920
- **KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study (vol 50, pg 123, 2016)** *LEUKEMIA RESEARCH*  
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, et al  
2017; 59: 65
- **MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma** *NATURE COMMUNICATIONS*

- Bailey, S. T., Smith, A. M., Kardos, J., Wobker, S. E., Wilson, H. L., Krishnan, B., Saito, R., Lee, H., Zhang, J., Eaton, S. C., Williams, L. A., Manocha, U., Peters, et al  
2017; 8: 15770
- **Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Gouw, A. M., Eberlin, L. S., Margulis, K., Sullivan, D. K., Toal, G. G., Tong, L., Zare, R. N., Felsher, D. W.  
2017; 114 (17): 4300-4305
  - **MYC: Master Regulator of Immune Privilege.** *Trends in immunology*  
Casey, S. C., Baylot, V., Felsher, D. W.  
2017
  - **KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.** *Leukemia research*  
Swords, R. T., Greenberg, P. L., Wei, A. H., Durrant, S., Advani, A. S., Hertzberg, M. S., Lewis, I. D., Rivera, G., Gratzinger, D., Fan, A. C., Felsher, D. W., Cortes, J. E., Watts, et al  
2016; 50: 123-131
  - **BIM-mediated apoptosis and oncogene addiction.** *Aging*  
Li, Y., Deutzmann, A., Felsher, D. W.  
2016; 8 (9): 1834-1835
  - **Affordable Cancer Medications Are Within Reach but We Need a Different Approach.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Felsher, D. W., Lowe, L.  
2016; 34 (18): 2194-5
  - **Metabolic vulnerabilities of MYC-induced cancer** *ONCOTARGET*  
Gouw, A. M., Toal, G. G., Felsher, D. W.  
2016; 7 (21): 29879-80
  - **BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia** *ONCOTARGET*  
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., Felsher, D. W.  
2016; 7 (19): 26926-26934
  - **BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.** *Oncotarget*  
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., Felsher, D. W.  
2016
  - **MYC regulates the antitumor immune response through CD47 and PD-L1** *SCIENCE*  
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., FitzGerald, K. N., Gouw, A. M., Baylot, V., Guetgemann, I., Eilers, M., Felsher, D. W.  
2016; 352 (6282): 227-231
  - **NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis** *NATURE*  
Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., Han, M., Thornton, A. M., Zhang, et al  
2016; 531 (7593): 253-?
  - **Cancer prevention and therapy through the modulation of the tumor microenvironment.** *Seminars in cancer biology*  
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilisland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., Crawford, S., Fujii, H., Georgakilas, et al  
2015; 35: S199-223
  - **Cancer prevention and therapy through the modulation of the tumor microenvironment.** *Seminars in cancer biology*  
Casey, S. C., Amedei, A., Aquilano, K., Azmi, A. S., Benencia, F., Bhakta, D., Bilisland, A. E., Boosani, C. S., Chen, S., Ciriolo, M. R., Crawford, S., Fujii, H., Georgakilas, et al  
2015; 35: S199-223
  - **Designing a broad-spectrum integrative approach for cancer prevention and treatment** *SEMINARS IN CANCER BIOLOGY*

- Block, K. I., Gyllenhaal, C., Lowe, L., Amedei, A., Amin, A. R., Amin, A., Aquilano, K., Arbiser, J., Arreola, A., Arzumanyan, A., Ashraf, S. S., Azmi, A. S., Benencia, et al  
2015; 35: S276-S304
- **MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.** *Cell metabolism*  
Altman, B. J., Hsieh, A. L., Sengupta, A., Krishnanaiah, S. Y., Stine, Z. E., Walton, Z. E., Gouw, A. M., Venkataraman, A., Li, B., Goraksha-Hicks, P., Diskin, S. J., Bellovin, D. I., Simon, et al  
2015; 22 (6): 1009-1019
  - **ARF: Connecting senescence and innate immunity for clearance** *AGING-US*  
Kearney, A. Y., Anchang, B., Plevritis, S., Felsher, D. W.  
2015; 7 (9): 613-615
  - **The effect of environmental chemicals on the tumor microenvironment** *CARCINOGENESIS*  
Casey, S. C., Vaccari, M., Al-Mulla, F., Al-Temaimi, R., Amedei, A., Barcellos-Hoff, M. H., Brown, D. G., Chapellier, M., Christopher, J., Curran, C., Forte, S., Hamid, R. A., Heneberg, et al  
2015; 36: S160-S183
  - **Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.** *Carcinogenesis*  
Goodson, W. H., Lowe, L., Carpenter, D. O., Gilbertson, M., Manaf Ali, A., Lopez de Cerain Salsamendi, A., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., Charles, A. K., Collins, A. R., Ward, et al  
2015; 36: S254-96
  - **Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis** *JOURNAL OF CLINICAL INVESTIGATION*  
Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O'Connor, R. S., Altman, B. J., Hsieh, A. L., Gouw, A. M., Thomas, A. G., Gao, P., Sun, L., Song, L., Yan, et al  
2015; 125 (6): 2293-2306
  - **Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead** *CARCINOGENESIS*  
Goodson, W. H., Lowe, L., Carpenter, D. O., Gilbertson, M., Ali, A. M., de Cerain Salsamendi, A. L., Lasfar, A., Carnero, A., Azqueta, A., Amedei, A., Charles, A. K., Collins, A. R., Ward, et al  
2015; 36: S254-S296
  - **MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Shroff, E. H., Eberlin, L. S., Dang, V. M., Gouw, A. M., Gabay, M., Adam, S. J., Bellovin, D. I., Tran, P. T., Philbrick, W. M., Garcia-Ocana, A., Casey, S. C., Li, Y., Dang, et al  
2015; 112 (21): 6539-6544
  - **p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia** *ONCOTARGET*  
Yetil, A., Anchang, B., Gouw, A. M., Adam, S. J., Zabuwala, T., Parameswaran, R., van Riggelen, J., Plevritis, S., Felsher, D. W.  
2015; 6 (6): 3563-3577
  - **miR-17-92 explains MYC oncogene addiction.** *Molecular & cellular oncology*  
Li, Y., Casey, S. C., Choi, P. S., Felsher, D. W.  
2014; 1 (4)
  - **Oncogene addiction: resetting the safety switch?** *Oncotarget*  
Li, Y., Choi, P. S., Felsher, D. W.  
2014; 5 (18): 7986-7987
  - **Activation of Cre Recombinase Alone Can Induce Complete Tumor Regression** *PLOS ONE*  
Li, Y., Choi, S., Casey, S. C., Felsher, D. W.  
2014; 9 (9)
  - **Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.** *Proceedings of the National Academy of Sciences of the United States of America*  
Choi, P. S., Li, Y., Felsher, D. W.  
2014; 111 (32): E3316-24

- **Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.** *Proceedings of the National Academy of Sciences of the United States of America*  
Choi, P. S., Li, Y., Felsher, D. W.  
2014; 111 (32): E3316-24
- **MYC through miR-17-92 Suppresses Specific Target Genes to Maintain Survival, Autonomous Proliferation, and a Neoplastic State.** *Cancer cell*  
Li, Y., Choi, P. S., Casey, S. C., Dill, D. L., Felsher, D. W.  
2014; 26 (2): 262-272
- **Alteration of the lipid profile in lymphomas induced by MYC overexpression.** *Proceedings of the National Academy of Sciences of the United States of America*  
Eberlin, L. S., Gabay, M., Fan, A. C., Gouw, A. M., Tibshirani, R. J., Felsher, D. W., Zare, R. N.  
2014; 111 (29): 10450-10455
- **Inactivation of MYC reverses tumorigenesis** *JOURNAL OF INTERNAL MEDICINE*  
Li, Y., Casey, S. C., Felsher, D. W.  
2014; 276 (1): 52-60
- **MYC Activation Is a Hallmark of Cancer Initiation and Maintenance** *COLD SPRING HARBOR PERSPECTIVES IN MEDICINE*  
Gabay, M., Li, Y., Felsher, D. W.  
2014; 4 (6)
- **MYC activation is a hallmark of cancer initiation and maintenance.** *Cold Spring Harbor perspectives in medicine*  
Gabay, M., Li, Y., Felsher, D. W.  
2014; 4 (6)
- **Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo.** *Nature chemistry*  
Ye, D., Shuhendler, A. J., Cui, L., Tong, L., Tee, S. S., Tikhomirov, G., Felsher, D. W., Rao, J.  
2014; 6 (6): 519-526
- **An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.** *Immunologic research*  
Casey, S. C., Li, Y., Felsher, D. W.  
2014; 58 (2-3): 282-291
- **Inactivation of MYC reverses tumorigenesis.** *Journal of internal medicine*  
Li, Y., Casey, S. C., Felsher, D. W.  
2014
- **Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance.** *Cancer cell*  
Cao, Z., Ding, B., Guo, P., Lee, S. B., Butler, J. M., Casey, S. C., Simons, M., Tam, W., Felsher, D. W., Shido, K., Rafii, A., Scandura, J. M., Rafii, et al  
2014; 25 (3): 350-365
- **Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance** *CANCER CELL*  
Cao, Z., Ding, B., Guo, P., Lee, S. B., Butler, J. M., Casey, S. C., Simons, M., Tam, W., Felsher, D. W., Shido, K., Rafii, A., Scandura, J. M., Refii, et al  
2014; 25 (3): 350-365
- **Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy.** *Small*  
Ansari, C., Tikhomirov, G. A., Hong, S. H., Falconer, R. A., Loadman, P. M., Gill, J. H., Castaneda, R., Hazard, F. K., Tong, L., Lenkov, O. D., Felsher, D. W., Rao, J., Daldrup-Link, et al  
2014; 10 (3): 566-?
- **Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy.** *Small*  
Ansari, C., Tikhomirov, G. A., Hong, S. H., Falconer, R. A., Loadman, P. M., Gill, J. H., Castaneda, R., Hazard, F. K., Tong, L., Lenkov, O. D., Felsher, D. W., Rao, J., Daldrup-Link, et al  
2014; 10 (3): 566-575
- **Oncogene withdrawal engages the immune system to induce sustained cancer regression.** *Journal for immunotherapy of cancer*

- Casey, S. C., Li, Y., Fan, A. C., Felsher, D. W.  
2014; 2: 24-?
- **Activation of Cre recombinase alone can induce complete tumor regression.** *PLoS one*  
Li, Y., Choi, P. S., Casey, S. C., Felsher, D. W.  
2014; 9 (9)
  - **STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma** *ONCOGENE*  
Bisikirska, B. C., Adam, S. J., Alvarez, M. J., Rajbhandari, P., Cox, R., Lefebvre, C., Wang, K., Rieckhof, G. E., Felsher, D. W., Califano, A.  
2013; 32 (45): 5283-5291
  - **Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma** *JOURNAL OF HEPATOLOGY*  
Kapanadze, T., Gamrekelashvili, J., Ma, C., Chan, C., Zhao, F., Hewitt, S., Zender, L., Kapoor, V., Felsher, D. W., Manns, M. P., Korangy, F., Greten, T. F.  
2013; 59 (5): 1007-1013
  - **Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.** *Expert opinion on investigational drugs*  
Fan, A. C., O'Rourke, J. J., Praharaj, D. R., Felsher, D. W.  
2013; 22 (11): 1495-1509
  - **BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.** *Blood*  
Beurlet, S., Omidvar, N., Gorombeï, P., Krief, P., Le Pogam, C., Setterblad, N., de la Grange, P., Leboeuf, C., Janin, A., Noguera, M., Hervatin, F., Sarda-Mantel, L., Konopleva, et al  
2013; 122 (16): 2864-2876
  - **A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide.** *Molecular cancer therapeutics*  
Fan-Minogue, H., Bodapati, S., Solow-Cordero, D., Fan, A., Paulmurugan, R., Massoud, T. F., Felsher, D. W., Gambhir, S. S.  
2013; 12 (9): 1896-1905
  - **A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation.** *Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference*  
Nwbugwu, C. I., Rakhra, K., Felsher, D. W., Paik, D. S.  
2013; 2013: 4529-4532
  - **Characterization of MYC-Induced Tumorigenesis by in Situ Lipid Profiling** *ANALYTICAL CHEMISTRY*  
Perry, R. H., Bellovin, D. I., Shroff, E. H., Ismail, A. I., Zabuawala, T., Felsher, D. W., Zare, R. N.  
2013; 85 (9): 4259-4262
  - **[F-18]CAIP a smart PET tracer for imaging caspase-3 induced Apoptosis**  
Shen Bin, B., Jeon, J., Palner, M., Tong Ling, L., Felsher, D., Gambhir, S. S., Chin, F. T., Rao Jianghong, J. H.  
WILEY-BLACKWELL.2013: S6-S6
  - **Role of MYCN in retinoblastoma** *LANCET ONCOLOGY*  
Felsher, D. W.  
2013; 14 (4): 270-271
  - **Noncanonical roles of the immune system in eliciting oncogene addiction.** *Current opinion in immunology*  
Casey, S. C., Bellovin, D. I., Felsher, D. W.  
2013; 25 (2): 246-258
  - **Metabolic changes in cancer cells upon suppression of MYC.** *Cancer & metabolism*  
Anso, E., Mullen, A. R., Felsher, D. W., Matés, J. M., DeBerardinis, R. J., Chandel, N. S.  
2013; 1 (1): 7-?
  - **Dissection of the role of the tumor microenvironment in oncogene addiction by ex vivo and in situ imaging** *AACR/SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy*

- Tong, L., Jeon, J., Shen, B., Jianghong, R., Chin, F., Gambhir, S., Felsher, D.  
SOC NUCLEAR MEDICINE INC.2013: 25–25
- **CD271(+)** bone marrow mesenchymal stem cells may provide a niche for dormant *Mycobacterium tuberculosis*. *Science translational medicine*  
Das, B., Kashino, S. S., Pulu, I., Kalita, D., Swami, V., Yeger, H., Felsher, D. W., Campos-Neto, A.  
2013; 5 (170): 170ra13-?
  - **CD271(+)** Bone Marrow Mesenchymal Stem Cells May Provide a Niche for Dormant *Mycobacterium tuberculosis* *SCIENCE TRANSLATIONAL MEDICINE*  
Das, B., Kashino, S. S., Pulu, I., Kalita, D., Swami, V., Yeger, H., Felsher, D. W., Campos-Neto, A.  
2013; 5 (170)
  - **In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth.** *Computational and mathematical methods in medicine*  
Nwabugwu, C., Rakhra, K., Felsher, D., Paik, D.  
2013; 2013: 802512-?
  - **In Vivo Imaging-Based Mathematical Modeling Techniques That Enhance the Understanding of Oncogene Addiction in relation to Tumor Growth** *COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE*  
Nwabugwu, C., Rakhra, K., Felsher, D., Paik, D.  
2013
  - **Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.** *Methods in molecular biology (Clifton, N.J.)*  
Rakhra, K., Felsher, D. W.  
2013; 1012: 221-235
  - **Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.** *Advances in experimental medicine and biology*  
Bellovin, D. I., Das, B., Felsher, D. W.  
2013; 734: 91-107
  - **SIRT1 and c-Myc Promote Liver Tumor Cell Survival and Predict Poor Survival of Human Hepatocellular Carcinomas** *PLOS ONE*  
Jang, K. Y., Noh, S. J., Lehwald, N., Tao, G., Bellovin, D. I., Park, H. S., Moon, W. S., Felsher, D. W., Sylvester, K. G.  
2012; 7 (9)
  - **HIF-2 alpha Suppresses p53 to Enhance the Stemness and Regenerative Potential of Human Embryonic Stem Cells** *STEM CELLS*  
Das, B., Bayat-Mokhtari, R., Tsui, M., Lotfi, S., Tsuchida, R., Felsher, D. W., Yeger, H.  
2012; 30 (8): 1685-1695
  - **Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis** *PLOS GENETICS*  
Tran, P. T., Shroff, E. H., Burns, T. F., Thiyagarajan, S., Das, S. T., Zabuawala, T., Chen, J., Cho, Y., Luong, R., Tamayo, P., Salih, T., Aziz, K., Adam, et al  
2012; 8 (5)
  - **Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction** *CLINICAL AND EXPERIMENTAL IMMUNOLOGY*  
Bachireddy, P., Rakhra, K., Felsher, D. W.  
2012; 167 (2): 188-194
  - **Loss of Dnmt3b function upregulates the tumor modifier Mnt and accelerates mouse lymphomagenesis** *JOURNAL OF CLINICAL INVESTIGATION*  
Hlady, R. A., Novakova, S., Opavska, J., Klinkebiel, D., Peters, S. L., Bies, J., Hannah, J., Iqbal, J., Anderson, K. M., Siebler, H. M., Smith, L. M., Greiner, T. C., Bastola, et al  
2012; 122 (1): 163-177
  - **Mathematical Modeling of the Interactions between Cellular Programs in Response to Oncogene Inactivation** *12th IEEE International Conference on BioInformatics and BioEngineering (BIBE)*  
Nwabugwu, C., Rakhra, K., Felsher, D., Paik, D.  
IEEE.2012: 454–459

- **Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na** *LEUKEMIA RESEARCH*  
Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K., Wilhelm, F., Greenberg, P. L.  
2012; 36 (1): 98-103
- **"Picolog," a Synthetically-Available Bryostatins Analog, Inhibits Growth of MYC-Induced Lymphoma In Vivo** *ONCOTARGET*  
DeChristopher, B. A., Fan, A. C., Felsher, D. W., Wender, P. A.  
2012; 3 (1): 58-66
- **Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin's lymphoma treated with PEP-C.** *BMJ case reports*  
To, C. A., Hsieh, R. W., McClellan, J. S., Howard, W., Fischbein, N. J., Brown, J. M., Felsher, D. W., Fan, A. C.  
2012; 2012
- **High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation** *LAB ON A CHIP*  
Wu, A. R., Kawahara, T. L., Rapicavoli, N. A., van Riggelen, J., Shroff, E. H., Xu, L., Felsher, D. W., Chang, H. Y., Quake, S. R.  
2012; 12 (12): 2190-2198
- **Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas** *LEUKEMIA*  
Dejean, E., Renalier, M. H., Foisseau, M., Agirre, X., Joseph, N., De Paiva, G. R., Al Saati, T., Soulier, J., Desjobert, C., Lamant, L., Prosper, F., Felsher, D. W., Cavaille, et al  
2011; 25 (12): 1882-1890
- **A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Fan, A. C., Xu, L., Sridhar, K. J., Tran, M., Banerjee, P., Renschler, J. P., Tripuraneni, R., Wilhelm, F., Greenberg, P. L., Felsher, D. W.  
AMER SOC HEMATOLOGY.2011: 1626-26
- **Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Choi, P. S., van Riggelen, J., Gentles, A. J., Bachireddy, P., Rakhra, K., Adam, S. J., Plevritis, S. K., Felsher, D. W.  
2011; 108 (42): 17432-17437
- **Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation** *SCIENCE TRANSLATIONAL MEDICINE*  
Tran, P. T., Bendapudi, P. K., Lin, H. J., Choi, P., Koh, S., Chen, J., Hornig, G., Hughes, N. P., Schwartz, L. H., Miller, V. A., Kawashima, T., Kitamura, T., Paik, et al  
2011; 3 (103)
- **Functional Interactions between Retinoblastoma and c-MYC in a Mouse Model of Hepatocellular Carcinoma** *PLOS ONE*  
Saddic, L. A., Wirt, S., Vogel, H., Felsher, D. W., Sage, J.  
2011; 6 (5)
- **Reactive Oxygen Species Regulate Nucleostemin Oligomerization and Protein Degradation** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Huang, M., Whang, P., Chodaparambil, J. V., Pollyea, D. A., Kusler, B., Xu, L., Felsher, D. W., Mitchell, B. S.  
2011; 286 (13): 11035-11046
- **MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase** *CANCER RESEARCH*  
Cao, Z., Fan-Minogue, H., Bellovin, D. I., Yevtdiyenko, A., Arzeno, J., Yang, Q., Gambhir, S. S., Felsher, D. W.  
2011; 71 (6): 2286-2297
- **Definition of an Enhanced Immune Cell Therapy in Mice That Can Target Stem-Like Lymphoma Cells** *CANCER RESEARCH*  
Contag, C. H., Sikorski, R., Negrin, R. S., Schmidt, T., Fan, A. C., Bachireddy, P., Felsher, D. W., Thorne, S. H.  
2010; 70 (23): 9837-9845
- **TGF $\beta$ -dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas.** *Cell cycle*  
Müller, J., Samans, B., van Riggelen, J., Fagà, G., Peh K N, R., Wei, C., Müller, H., Amati, B., Felsher, D., Eilers, M.  
2010; 9 (23): 4622-4626

- **TGFbeta-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas** *CELL CYCLE*  
Mueller, J., Samans, B., van Riggelen, J., Faga, G., Peh, R. K., Wei, C., Mueller, H., Amati, B., Felsher, D., Eilers, M.  
2010; 9 (23): 4622-4626
- **ABT-737 Targets Leukemic Stem Cells in Mouse Models of Mutant NRASD12/hBCL-2-Mediated Acute Myeloid Leukemia progression with Increased Survival** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Padua, R. A., Beurlet, S., Krief, P., Omidvar, N., Le Pogam, C., Auboeuf, D., de la Grange, P., Soulie, A., Janin, A., Noguera, M., Merlet, P., Sarda-Mantel, L., Fenaux, et al  
AMER SOC HEMATOLOGY.2010: 1355-56
- **Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*  
Seetharam, M., Tran, M., Fan, A. C., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K., Wilhelm, F., Greenberg, P. L.  
AMER SOC HEMATOLOGY.2010: 1635-35
- **CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation** *CANCER CELL*  
Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., Ryeom, S., Felsher, D. W.  
2010; 18 (5): 485-498
- **PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel Cu-64-DOTA-Knottin Peptide** *CANCER RESEARCH*  
Nielsen, C. H., Kimura, R. H., Withofs, N., Tran, P. T., Miao, Z., Cochran, J. R., Cheng, Z., Felsher, D., Kjaer, A., Willmann, J. K., Gambhir, S. S.  
2010; 70 (22): 9022-9030
- **Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics** *CLINICAL CANCER RESEARCH*  
Graves, E. E., Vilalta, M., Cecic, I. K., Erler, J. T., Tran, P. T., Felsher, D., Sayles, L., Sweet-Cordero, A., Le, Q., Giaccia, A. J.  
2010; 16 (19): 4843-4852
- **Noninvasive molecular imaging of c-Myc activation in living mice** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Fan-Minogue, H., Cao, Z., Paulmurugan, R., Chan, C. T., Massoud, T. F., Felsher, D. W., Gambhir, S. S.  
2010; 107 (36): 15892-15897
- **DEVELOPMENT OF A MICRO-COMPUTED TOMOGRAPHY-BASED IMAGE-GUIDED CONFORMAL RADIOTHERAPY SYSTEM FOR SMALL ANIMALS** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*  
Zhou, H., Rodriguez, M., van den Haak, F., Nelson, G., Jogani, R., Xu, J., Zhu, X., Xian, Y., Tran, P. T., Felsher, D. W., Keall, P. J., Graves, E. E.  
2010; 78 (1): 297-305
- **Impact of Hydrodynamic Injection and phiC31 Integrase on Tumor Latency in a Mouse Model of MYC-Induced Hepatocellular Carcinoma** *PLOS ONE*  
Woodard, L. E., Keravala, A., Jung, W. E., Wapinski, O. L., Yang, Q., Felsher, D. W., Calos, M. P.  
2010; 5 (6)
- **The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance.** *Genes & development*  
van Riggelen, J., Müller, J., Otto, T., Beuger, V., Yetil, A., Choi, P. S., Kosan, C., Mörröy, T., Felsher, D. W., Eilers, M.  
2010; 24 (12): 1281-1294
- **The interaction between Myc and Miz1 is required to antagonize TGF beta-dependent autocrine signaling during lymphoma formation and maintenance** *GENES & DEVELOPMENT*  
van Riggelen, J., Mueller, J., Otto, T., Beuger, V., Yetil, A., Choi, P. S., Kosan, C., Moeröy, T., Felsher, D. W., Eilers, M.  
2010; 24 (12): 1281-1294
- **MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.** *Genes & cancer*  
Felsher, D. W.  
2010; 1 (6): 597-604
- **Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia** *BLOOD*  
Giuriato, S., Foisseau, M., Dejean, E., Felsher, D. W., Al Saati, T., Demur, C., Ragab, A., Kruczynski, A., Schiff, C., Delsol, G., Meggetto, F.

2010; 115 (20): 4061-4070

- **MYC as a regulator of ribosome biogenesis and protein synthesis** *NATURE REVIEWS CANCER*  
van Riggelen, J., Yetil, A., Felsher, D. W.  
2010; 10 (4): 301-309
- **Myc and a Cdk2 senescence switch** *NATURE CELL BIOLOGY*  
van Riggelen, J., Felsher, D. W.  
2010; 12 (1): 7-9
- **Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice** *MOLECULAR THERAPY*  
Beer, S., Bellovin, D. I., Lee, J. S., Komatsubara, K., Wang, L. S., Koh, H., Boerner, K., Storm, T. A., Davis, C. R., Kay, M. A., Felsher, D. W., Grimm, D.  
2010; 18 (1): 161-170
- **Cell Cycle Re-Entry and Mitochondrial Defects in Myc-Mediated Hypertrophic Cardiomyopathy and Heart Failure** *PLOS ONE*  
Lee, H., Chen, Q., Wolfram, J. A., Richardson, S. L., Liner, A., Siedlak, S. L., Zhu, X., Ziats, N. P., Fujioka, H., Felsher, D. W., Castellani, R. J., Valencik, M. L., McDonald, et al  
2009; 4 (9)
- **Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens** *NATURE MEDICINE*  
Fan, A. C., Deb-Basu, D., Orban, M. W., Gotlib, J. R., Natkunam, Y., O'Neill, R., Padua, R., Xu, L., Taketa, D., Shirer, A. E., Beer, S., Yee, A. X., Voehringer, et al  
2009; 15 (5): 566-571
- **SPECT and PET Imaging of EGF Receptors with Site-Specifically Labeled EGF and Dimeric EGF** *BIOCONJUGATE CHEMISTRY*  
Levashova, Z., Backer, M. V., Horng, G., Felsher, D., Backer, J. M., Blankenberg, F. G.  
2009; 20 (4): 742-749
- **Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Kampa, K. M., Acoba, J. D., Chen, D., Gay, J., Lee, H., Beemer, K., Padiernos, E., Boonmark, N., Zhu, Z., Fan, A. C., Bailey, A. S., Fleming, W. H., Corless, et al  
2009; 106 (11): 4390-4395
- **The Neuronal Expression of MYC Causes a Neurodegenerative Phenotype in a Novel Transgenic Mouse** *AMERICAN JOURNAL OF PATHOLOGY*  
Lee, H., Casadesus, G., Nunomura, A., Zhu, X., Castellani, R. J., Richardson, S. L., Perry, G., Felsher, D. W., Petersen, R. B., Smith, M. A.  
2009; 174 (3): 891-897
- **Autochthonous Liver Tumors Induce Systemic T Cell Tolerance Associated with T Cell Receptor Down-Modulation** *HEPATOLOGY*  
Ney, J. T., Schmidt, T., Kurts, C., Zhou, Q., Eckert, D., Felsher, D. W., Schorle, H., Knolle, P., Tueting, T., Barchet, W., Buettner, R., Limnier, A., Guetgemann, et al  
2009; 49 (2): 471-481
- **Supramolecular Stacking of Doxorubicin on Carbon Nanotubes for In Vivo Cancer Therapy** *ANGEWANDTE CHEMIE-INTERNATIONAL EDITION*  
Liu, Z., Fan, A. C., Rakhra, K., Sherlock, S., Goodwin, A., Chen, X., Yang, Q., Felsher, D. W., Dai, H.  
2009; 48 (41): 7668-7672
- **The current STATE of biomarkers to predict the response to anti-angiogenic therapies** *CANCER BIOLOGY & THERAPY*  
Tran, P. T., Felsher, D. W.  
2008; 7 (12): 2004-2006
- **F-18 and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation** *CANCER BIOLOGY & THERAPY*  
Arvanitis, C., Bendapudi, P. K., Tseng, J. R., Gambhir, S. S., Felsher, D. W.  
2008; 7 (12): 1947-1951
- **A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice** *MOLECULAR CANCER*  
Fan, A. C., Goldrick, M. M., Ho, J., Liang, Y., Bachireddy, P., Felsher, D. W.

2008; 7

- **An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice** *NATURE MEDICINE*  
Traykova-Brauch, M., Schoenig, K., Greiner, O., Miloud, T., Jauch, A., Bode, M., Felsher, D. W., Glick, A. B., Kwiatkowski, D. J., Bujard, H., Horst, J., Doeberitz, M. v., Niggli, et al  
2008; 14 (9): 979-984
- **Tumor dormancy and oncogene addiction** *APMIS*  
Felsher, D. W.  
2008; 116 (7-8): 629-637
- **Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance** *CANCER RESEARCH*  
Shachaf, C. M., Gentles, A. J., Elchuri, S., Sahoo, D., Soen, Y., Sharpe, O., Perez, O. D., Chang, M., Mitchel, D., Robinson, W. H., Dill, D., Nolan, G. P., Plevritis, et al  
2008; 68 (13): 5132-5142
- **Hepatotoxin-Induced Changes in the Adult Murine Liver Promote MYC-Induced Tumorigenesis** *PLOS ONE*  
Beer, S., Komatsubara, K., Bellovin, D. I., Kurobe, M., Sylvester, K., Felsher, D. W.  
2008; 3 (6)
- **Combined Analysis of Murine and Human Microarrays and ChIP Analysis Reveals Genes Associated with the Ability of MYC To Maintain Tumorigenesis** *PLOS GENETICS*  
Wu, C., Sahoo, D., Arvanitis, C., Bradon, N., Dill, D. L., Felsher, D. W.  
2008; 4 (6)
- **Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas** *PLOS ONE*  
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., Whitsett, J. A., Felsher, D. W.  
2008; 3 (5)
- **Oncogene addiction versus oncogene amnesia: Perhaps more than just a bad habit?** *CANCER RESEARCH*  
Felsher, D. W.  
2008; 68 (9): 3081-3086
- **Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch.** *Lymphatic research and biology*  
Felsher, D. W.  
2008; 6 (3-4): 149-154
- **MYC potentiates DNA damage response dependent cellular senescence** *50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*  
Tran, P. T., Chen, J., Choi, P., Horng, G., Felsher, D. W.  
ELSEVIER SCIENCE INC.2008: S693-S693
- **BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia** *CANCER RESEARCH*  
Omidvar, N., Kogan, S., Beurlet, S., Pogam, C. I., Janin, A., West, R., Noguera, M., Reboul, M., Soulie, A., Leboeuf, C., Setterblad, N., Felsher, D., Lagasse, et al  
2007; 67 (24): 11657-11667
- **A novel nano-immunoassay system capable of absolute protein measurements from 400 tumor-derived stem cells.**  
Voehringer, D. W., Deb-Basu, D., Weissman, I., Fan, A., Nguyen, U., Bhamidipati, A., Felsher, D. W.  
AMER ASSOC CANCER RESEARCH.2007: 3556S-3556S
- **Inhibition of HMGCoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis** *BLOOD*  
Shachaf, C. M., Perez, O. D., Youssef, S., Fan, A. C., Elchuri, S., Goldstein, M. J., Shirer, A. E., Sharpe, O., Chen, J., Mitchell, D. J., Chang, M., Nolan, G. P., Steinman, et al  
2007; 110 (7): 2674-2684
- **Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Opavsky, R., Tsai, S., Guimond, M., Arora, A., Opavska, J., Becknell, B., Kaufmann, M., Walton, N. A., Stephens, J. A., Fernandez, S. A., Muthusamy, N., Felsher, D. W., Porcu, et al

2007; 104 (39): 15400-15405

- **HIF-dependent antitumorigenic effect of antioxidants in vivo** *CANCER CELL*  
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwala, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., Lee, L. A., Semenza, G. L., Dang, et al  
2007; 12 (3): 230-238
- **CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells** *PLOS GENETICS*  
Opavsky, R., Wang, S., Trikha, P., Raval, A., Huang, Y., Wu, Y., Rodriguez, B., Keller, B., Liyanarachchi, S., Wei, G., Davuluri, R. V., Weinstein, M., Felsher, et al  
2007; 3 (9): 1757-1769
- **Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Wu, C., van Riggelen, J., Yetil, A., Fan, A. C., Bachireddy, P., Felsher, D. W.  
2007; 104 (32): 13028-13033
- **Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-Dependent cancer targeted therapy** *CANCER BIOLOGY & THERAPY*  
Giuriato, S., Faumont, N., Bousquet, E., Foisseau, M., Bibonne, A., Moreau, M., Saati, T. A., Felsher, D. W., Delsol, G., Meggetto, F.  
2007; 6 (8): 1318-1323
- **Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation** *JOURNAL OF IMMUNOLOGY*  
Pan, M., Winslow, M. M., Chen, L., Kuo, A., Felsher, D., Crabtree, G. R.  
2007; 178 (7): 4315-4321
- **Identifying critical signaling molecules for the treatment of cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer**  
Arvanitis, C., Bendapudi, P. K., Bachireddy, P., Felsher, D. W.  
2007; 172: 5-24
- **Predictive modeling of tumor regression kinetics using a murine model of oncogene-addicted lung cancers** *49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*  
Tran, P. T., Lin, J., Bendapudi, P., Koh, S., Komatsubara, K., Horng, G., Chen, J., Shachaf, C., Paik, D., Felsher, D. W.  
ELSEVIER SCIENCE INC.2007: S596-S597
- **ASPP2 haploinsufficiency promotes tumor formation in a mouse model.** *48th Annual Meeting of the American-Society-of-Hematology*  
Kampa, K. M., Acoba, J. D., Chen, D., Beemer, K., Gay, J., Zhu, Z., Padiernos, E., Fan, A., Felsher, D., Corless, C., Naumovski, L., Lopez, C. D.  
AMER SOC HEMATOLOGY.2006: 162B-162B
- **Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Giuriato, S., Ryeom, S., Fan, A. C., Bachireddy, P., Lynch, R. C., Rieth, M. J., van Riggelen, J., Kopelman, A. M., Passegue, E., Tang, F., Folkman, J., Felsher, D. W.  
2006; 103 (44): 16266-16271
- **Tumor dormancy - Death and resurrection of cancer as seen through transgenic mouse models** *CELL CYCLE*  
Felsher, D. W.  
2006; 5 (16): 1808-1811
- **Conditional transgenic models define how MYC initiates and maintains tumorigenesis** *SEMINARS IN CANCER BIOLOGY*  
Arvanitis, C., Felsher, D. W.  
2006; 16 (4): 313-317
- **c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma** *GENES & DEVELOPMENT*  
Weng, A. P., Millholland, J. M., Yashiro-Ohtani, Y., Arcangeli, M. L., Lau, A., Wai, C., del Bianco, C., Rodriguez, C. G., Sai, H., Tobias, J., Li, Y., Wolfe, M. S., Shachaf, et al  
2006; 20 (15): 2096-2109
- **MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species** *CANCER RESEARCH*  
Ray, S., Atkuri, K. R., Deb-Basu, D., Adler, A. S., Chang, H. Y., Herzenberg, L. A., Felsher, D. W.

2006; 66 (13): 6598-6605

- **CDK2 is required by MYC to induce apoptosis** *CELL CYCLE*  
Deb-Basu, D., Aleem, E., Kaldis, P., Felsher, D. W.  
2006; 5 (12): 1342-1347
- **MYC can enforce cell cycle transit from G(1) to S and G(2) to S, but not mitotic cellular division, independent of p27-mediated inhibition of Cyclin E/CDK2** *CELL CYCLE*  
Deb-Basu, D., Karlsson, A., Li, Q., Dang, C. V., Felsher, D. W.  
2006; 5 (12): 1348-1355
- **Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus tax** *JOURNAL OF BIOLOGICAL CHEMISTRY*  
Kwon, H., Ogle, L., Benitez, B., Bohuslav, J., Montano, M., Felsher, D. W., Greene, W. C.  
2005; 280 (42): 35713-35722
- **Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model** *ONCOGENE*  
Sander, S., Bullinger, L., Karlsson, A., Giuriato, S., Hernandez-Boussard, T., Felsher, D. W., Pollack, J. R.  
2005; 24 (40): 6101-6107
- **Conditionally MYC : insights from novel transgenic models** *CANCER LETTERS*  
Arvanitis, C., Felsher, D. W.  
2005; 226 (2): 95-99
- **Suppression of p53 by Notch in lymphomagenesis: Implications for initiation and regression** *CANCER RESEARCH*  
Beverly, L. J., Felsher, D. W., Capobianco, A. J.  
2005; 65 (16): 7159-7168
- **Rehabilitation of cancer through oncogene inactivation** *TRENDS IN MOLECULAR MEDICINE*  
Shachaf, C. M., Felsher, D. W.  
2005; 11 (7): 316-321
- **Getting at MYC through RAS** *CLINICAL CANCER RESEARCH*  
Bachireddy, P., Bendapudi, P. K., Felsher, D. W.  
2005; 11 (12): 4278-4281
- **Tumor dormancy and MYC inactivation: Pushing cancer to the brink of normalcy** *CANCER RESEARCH*  
Shachaf, C. M., Felsher, D. W.  
2005; 65 (11): 4471-4474
- **Developmental context determines latency of MYC-induced tumorigenesis** *PLOS BIOLOGY*  
Beer, S., Zetterberg, A., Ihrie, R. A., McTaggart, R. A., Yang, Q. W., Bradon, N., Arvanitis, C., Attardi, L. D., Feng, S., Ruebner, B., Cardiff, R. D., Felsher, D. W.  
2004; 2 (11): 1785-1798
- **MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer** *NATURE*  
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, A., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., Yang, Q. W., BISHOP, J. M., Contag, et al  
2004; 431 (7012): 1112-1117
- **Putting oncogenes into a developmental context** *CANCER BIOLOGY & THERAPY*  
Felsher, D. W.  
2004; 3 (10): 942-944
- **The human BCL6 transgene promotes the development of lymphomas in the mouse** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Baron, B. W., Anastasi, J., Montag, A., Huo, D. Z., Baron, R. M., Karrison, T., Thirman, M. J., Subudhi, S. K., Chin, R. K., Felsher, D. W., Fu, Y. X., McKeithan, T. W., Baron, et al  
2004; 101 (39): 14198-14203
- **The E47 transcription factor negatively regulates CD5 expression during thymocyte development** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*

- Yang, Y., Contag, C. H., Felsher, D., Shachaf, C. M., Cao, Y., Herzenberg, L. A., Herzenberg, L. A., Tung, J. W.  
2004; 101 (11): 3898-3902
- **Reversibility of oncogene-induced cancer** *CURRENT OPINION IN GENETICS & DEVELOPMENT*  
Felsher, D. W.  
2004; 14 (1): 37-42
  - **Oncogenes as therapeutic targets** *SEMINARS IN CANCER BIOLOGY*  
Felsher, D. W.  
2004; 14 (1): 1-1
  - **Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer** *SEMINARS IN CANCER BIOLOGY*  
Giuriato, S., Rabin, K., Fan, A. C., Shachaf, C. M., Felsher, D. W.  
2004; 14 (1): 3-11
  - **RAS and BCL-2 co-operate in a mouse model of myelodysplasia (MDS).** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*  
Padua, R. A., Chomienne, C., Kogan, S., Phan, T. H., Robledo, M., Muszlak, S., Felsher, D., Lagasse, E., Weismann, I., Whittaker, J., Janin, A., West, R., Pla, et al  
AMER SOC HEMATOLOGY.2003: 145A-145A
  - **Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*  
Karlsson, A., Deb-Basu, D., Cherry, A., Turner, S., Ford, J., Felsher, D. W.  
2003; 100 (17): 9974-9979
  - **How cancers escape their oncogene habit.** *Cell cycle*  
Giuriato, S., Felsher, D. W.  
2003; 2 (4): 329-332
  - **Pharmacological inactivation of MYC for the treatment of cancer** *DRUG NEWS & PERSPECTIVES*  
Felsher, D. W., Bradon, N.  
2003; 16 (6): 370-374
  - **Cancer revoked: oncogenes as therapeutic targets** *NATURE REVIEWS CANCER*  
Felsher, D. W.  
2003; 3 (5): 375-380
  - **Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations** *BLOOD*  
Karlsson, A., Giuriato, S., Tang, F., Fung-Weier, J., Levan, G., Felsher, D. W.  
2003; 101 (7): 2797-2803
  - **How Cancers Escape Their Oncogene Habit** *CELL CYCLE*  
Giuriato, S., Felsher, D. W.  
2003; 2 (4): 329-332
  - **Sustained loss of a neoplastic phenotype by brief inactivation of MYC** *SCIENCE*  
Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C. D., BISHOP, J. M., Felsher, D. W.  
2002; 297 (5578): 102-104
  - **C-Myc is a critical target for C/EBP alpha in granulopoiesis** *MOLECULAR AND CELLULAR BIOLOGY*  
Johansen, L. M., Iwama, A., Lodie, T. A., Sasaki, K., Felsher, D. W., Golub, T. R., Tenen, D. G.  
2001; 21 (11): 3789-3806
  - **Over-expression of MYC causes p53-dependent G2 arrest of normal fibroblasts**  
Felsher, D. W., Zetterberg, A., Zhu, J. Y., Tlsty, T., BISHOP, J. M.  
AMER SOC CELL BIOLOGY.2000: 239A-239A
  - **Overexpression of MYC causes p53-dependent G(2) arrest of normal fibroblasts** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*

---

Felsher, D. W., Zetterberg, A., Zhu, J. Y., Tlsty, T., BISHOP, J. M.  
2000; 97 (19): 10544-10548

- **Reversible tumorigenesis by MYC in hematopoietic lineages** *MOLECULAR CELL*  
Felsher, D. W., BISHOP, J. M.  
1999; 4 (2): 199-207
- **Transient excess of MYC activity can elicit genomic instability and tumorigenesis**  
Felsher, D. W., BISHOP, J. M.  
NATL ACAD SCIENCES.1999: 3940-44
- **A NOVEL OCTAMER REGULATORY ELEMENT IN THE V(H)11 LEADER EXON OF B-1 CELLS** *JOURNAL OF IMMUNOLOGY*  
Goodglick, L., Felsher, D. W., Neshat, M. S., Braun, J.  
1995; 154 (9): 4546-4556
- **C-MYC, MHCI, AND NK RESISTANCE IN IMMUNODEFICIENCY LYMPHOMAS** *ANNALS OF THE NEW YORK ACADEMY OF SCIENCES*  
Braun, J., Felsher, D. W., Goodglick, L. A.  
1992; 651: 467-469
- **C-MYC, MHCI, AND NK RESISTANCE IN IMMUNODEFICIENCY LYMPHOMAS** *CONF ON CD5 B-CELLS IN DEVELOPMENT AND DISEASE*  
Braun, J., Felsher, D. W., Goodglick, L. A.  
NEW YORK ACAD SCIENCES.1992: 467-469
- **INDEPENDENT REARRANGEMENT OF IG LAMBDA-GENES IN TISSUE CULTURE-DERIVED MURINE B-CELL LINES** *INTERNATIONAL IMMUNOLOGY*  
Felsher, D. W., ANDO, D. T., Braun, J.  
1991; 3 (7): 711-718
- **A MURINE MODEL FOR B-CELL LYMPHOMAGENESIS IN IMMUNOCOMPROMISED HOSTS - NATURAL-KILLER-CELLS ARE AN IMPORTANT COMPONENT OF HOST-RESISTANCE TO PREMALIGNANT B-CELL LINES** *CANCER RESEARCH*  
Felsher, D. W., Rhim, S. H., Braun, J.  
1990; 50 (21): 7050-7056
- **A MURINE MODEL FOR B-CELL LYMPHOMAGENESIS IN IMMUNOCOMPROMISED HOSTS - C-MYC-REARRANGED B-CELL LINES WITH A PREMALIGNANT PHENOTYPE** *CANCER RESEARCH*  
Felsher, D. W., DENIS, K. A., Weiss, D., ANDO, D. T., Braun, J.  
1990; 50 (21): 7042-7049
- **A RAPID METHOD FOR THE PURIFICATION OF MONOMERIC AND OR DIMERIC PHOSPHOLIPASES A2 IN CROTALID SNAKE-VENOMS** *TOXICON*  
WELCHES, W., Felsher, D., LANDSHULZ, W., Maraganore, J. M.  
1985; 23 (5): 747-754